Canada markets open in 4 hours 23 minutes

Takeda Pharmaceutical Company Limited (4502.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
3,748.00-17.00 (-0.45%)
At close: 03:15PM JST
Full screen
Previous Close3,765.00
Bid3,744.00 x 0
Ask3,749.00 x 0
Day's Range3,735.00 - 3,799.00
52 Week Range2,993.00 - 4,063.00
Avg. Volume5,534,009
Market Cap5.82T
Beta (5Y Monthly)0.80
PE Ratio (TTM)29.75
EPS (TTM)125.98
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & Yield180.00 (4.78%)
Ex-Dividend DateSept 29, 2022
1y Target EstN/A
  • Zacks

    TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

    TAK vs. ZTS: Which Stock Is the Better Value Option?

  • Zacks

    Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?

    The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • Reuters

    Takeda maintains annual guidance despite first-quarter profit drop

    TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.